drugset
drugset / Trial / NCT02095886

Relative Bioavailability Study With BMS-955176

NCT02095886 ↗

Phase 1 Completed 47 enrolled ViiV Healthcare GlaxoSmithKline · collab
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to select the best dose level (amount of drug given) and best formulation of the study drug (BMS-955176) to develop further.

Timeline

Start
2014-03-25
Primary completion
2014-07-07
Completion
2014-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-955176 Other / unclassified — Oral

Indications

HIV infectious disease